ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2025
[Current status of research on the impairment of natural killer cell function caused by hepatitis B virus infection].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Hepatitis B is a global health problem caused by hepatitis B virus (HBV) infection, with approximately 240 million people worldwide being hepatitis B surface antigen positive. However, existing antiviral therapies can only control HBV replication and cannot eliminate it, thereby seriously affecting the disease's prognosis. Immunotherapy has received widespread attention in recent years due to its long-lasting effects and safety profile. As one of the innate immune cells, natural killer cells play an important role in targeting HBV-infected cells and completely eliminating HBV infection. Natural killer cells can not only directly recognize and kill virus-infected cells but also regulate adaptive immune responses by secreting the cytokine interferon gamma. This article aims to review the regulatory relationship between natural killer cells and HBV-infected cells, research progress of natural killer cell-based immunotherapy targeting HBV infection, and explore the impact of natural killer cells on the occurrence and development of hepatocellular carcinoma in order to provide some enlightenment for improved treatment of HBV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.